ML Job Opportunities at AbSci!
Annie Zelko
AbSci is disrupting the traditional biopharmaceutical drug discovery process by reducing discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell lines for our partners. We are making AI a core technology with the Denovium Engine - a multidimensional deep learning model built to interpret, categorize, predict, and evolve function and behavior of proteins. We expect that the platform will be able to design proteins in silico by predicting not only the optimal sequence for each therapeutic candidate, but also the conditions for manufacturing, to enable production of therapeutic proteins that were previously not possible.
Some exciting features of this opportunity:
Impact. We are using AI deep learning to better predict relevant variants and cell line characteristics for each new project. With continued application and further training of the Denovium Engine, AbSci’s vision is to make in-silico biologic drug discovery and cell line development a reality. This will enable next-generation therapies to make it to market at unprecedented speeds.
Implementation. We act as an extension of the R&D teams at top biopharma companies. The partners we work with and our process allows us to get these drugs into the market more quickly and cost effectively than ever before.
Opportunity. AbSci intends to further train the Denovium Engine on its proprietary internally-generated multidimensional protein characterization datasets that include elements of protein functionality, expression, and manufacturability. The platform incorporates far more than sequence and structure relationships, having been trained on functional data from more than 100 million proteins and across over 700,000 descriptive parameters. With AbSci’s Protein Printing platform, you will have large amounts of data to work with.
Join a core team. You’ll be one of the core members working on the Denovium Engine - you will have a voice and contributions will be highly valued. You’ll not be one of many here.
About AbSci:
AbSci is a leading synthetic biology company that translates ideas into drugs with a revolutionary platform technology that disrupts the traditional biopharmaceutical drug discovery process. In one workflow, we select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for de novo discovery, our approach dramatically reduces biopharma discovery and development timelines from years to weeks by generating a GMP-ready manufacturing cell line for each asset. Incorporating deep learning will allow us to explore all possible protein sequences in silico, including those that Nature’s evolutionary trajectory has yet to consider, to identify drug candidates with optimal therapeutic properties and manufacturability. You can read more about us here: www.absci.com